Lenalidomid Zentiva

Lenalidomide, the active ingredient in Lenalidomid Zentiva, is an immunomodulatory drug presented as an oral tablet for oral administration. It is indicated for the treatment of adult patients with multiple myeloma and for certain myelodysplastic syndromes, where it helps control disease progression and related complications.

GNH USA supplies Lenalidomid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. All batches are consistently manufactured under EU Good Manufacturing Practice and meet stringent quality standards.

Lenalidomide is used in hematologic malignancies and related bone marrow disorders.

Multiple myeloma: reduces tumor burden and prolongs progression‑free survival in adult patients. Myelodysplastic syndromes with del(5q): improves blood counts and reduces transfusion dependence. Multiple myeloma (maintenance): helps maintain remission after autologous stem cell transplantation.

Lenalidomid Zentiva may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count. - Thrombocytopenia: lowered platelet levels. - Fatigue: persistent tiredness. - Nausea: feeling of sickness.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in veins. - Severe neutropenia or thrombocytopenia: risk of infection or bleeding. - Secondary primary malignancies: emergence of new cancers. - Hypersensitivity reactions: rash, fever, or anaphylaxis.

Before prescribing Lenalidomid Zentiva, clinicians should consider several safety measures.

Pregnancy: contraindicated; drug is teratogenic (Category X). Thrombosis risk: assess patient history and consider prophylaxis. Renal impairment: adjust dose based on renal function. Hematologic monitoring: perform regular CBC to detect cytopenias. Drug interactions: avoid concomitant use with strong CYP inducers. Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Lenalidomid Zentiva interacts with several medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce lenalidomide exposure. - Anticoagulants (warfarin): increased risk of thrombosis. - Live vaccines: heightened risk of infection.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (aspirin): additive bleeding risk. - CYP3A4 inhibitors (ketoconazole): may increase lenalidomide plasma levels. - Immunosuppressants (cyclosporine): potential for enhanced toxicity.